At a glance
- Originator Merck & Co
- Class Anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Migraine
Most Recent Events
- 17 May 1999 Phase-II clinical trials for Migraine in USA (Unknown route)
- 05 Dec 1997 Phase-II clinical trials for Inflammation in USA (PO)